Minesh Mehta, MBChB, talks about the recently FDA-approved Optune used to treat newly diagnosed glioblastoma. The device utilizes alternating electric fields to inhibit tumor cell growth.
Minesh Mehta, MBChB, medical director, Maryland Proton Treatment Center, talks about Optune, the recently FDA-approved device used to treat newly diagnosed glioblastoma. The system utilizes alternating electric fields to inhibit tumor cell growth.
Mehta says that he hopes the device will become more widespread in the future after more research comes out about its clinical benefit.
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More
Olaptesed Pegol Wins FDA Fast Track Designation in Brain Cancer
April 3rd 2024The FDA granted a fast track designation to olaptesed pegol with bevacizumab and radiotherapy for patients with newly diagnosed glioblastoma that is resistant to chemotherapy and where measurable tumor remains after surgery.
Read More